ClinicalTrialsFinder
RecruitingNot ApplicableNCT05646576

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study

Sponsor

Massachusetts General Hospital

Enrollment

90 participants

Start Date

Dec 30, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple MyelomaLymphomaLeukemiaHematologic MalignancyBlood Cancer

Summary

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether adding palliative care support — focused on comfort, symptom management, and quality of life — helps patients with blood cancers (like lymphoma or leukemia) who are undergoing CAR T-cell therapy or stem cell transplants. **You may be eligible if...** - You are 18 or older and have been diagnosed with a blood cancer - You are receiving an FDA-approved cell therapy (such as CAR T-cell therapy) at the study hospital - You are able to complete surveys in English or with an interpreter's help **You may NOT be eligible if...** - You are unable to communicate or complete surveys due to cognitive difficulties - You do not meet the specific cell therapy criteria at the participating site Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPalliative Care

* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers. * Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care. * The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot.

BEHAVIORALUsual Care

Standard care for ACT per the treating team.

Locations(1)

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05646576

Related Trials

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

NCT069040661 location

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location